
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion AS demonstrates a robust financial outlook, bolstered by Merck's (MRK) option exercise, which extends the company's cash runway into the first half of 2027, enabling progress on key milestones in its infectious disease and oncology pipelines. The extension and expansion of the EVX-B2 program's review by MRK is indicative of a strengthened likelihood for potential in-licensing, enhancing strategic partnerships and validation of Evaxion's AI-Immunology platform. Furthermore, the increasing collaboration with MRK, which holds approximately 20% ownership in Evaxion, underscores confidence in the company's innovative approaches to developing novel immunotherapies, further enhancing its market positioning.
Bears say
Evaxion AS faces a concerning outlook due to its reliance on unproven AI technology in the highly competitive biotech sector, which may delay the development and possible commercialization of its personalized vaccines and immunotherapies. Furthermore, the company's financial position appears strained, with limited cash reserves and significant ongoing expenses related to research and development, heightening risks associated with funding its clinical and preclinical pipelines. Additionally, challenges related to regulatory approvals and market adoption of novel therapies may impede revenue generation, further contributing to a negative financial outlook.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares